AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer¿s Disease and Elevated Amyloid (A45 Trial) and in Subjects With

Project Details

StatusActive
Effective start/end date1/01/20 → 31/12/24

Funding

  • University of Southern California: $1,591,544.00